Jayender Chintaparthi, MD
Endocrinology, Diabetes & Metabolism · Indianapolis, INNPI 1437486636
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,106 of the $4,975 with a category attached, or 82.5%. 34 manufacturers reported payments, led by AstraZeneca at 25.2% of the total.
Across 241 payments — averaging $20.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$603
- Medtronic$392
- Abbott$320
- Amgen$275
- Lilly USA, LLC$246
- plus $2K from 28 others
What the payments were for
- Consulting fees$79816%
- Food & beverage$4,10683%
- Education$120%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 16 | $1,254 |
| Novo Nordisk | 51 | $603 |
| Medtronic(2 entities) | 21 | $392 |
| Abbott | 21 | $320 |
| Amgen | 16 | $275 |
| Lilly USA, LLC | 13 | $246 |
| Insulet Corporation | 12 | $222 |
| Mannkind Corporation | 7 | $189 |
| Xeris Pharmaceuticals, Inc. | 9 | $173 |
| Boehringer Ingelheim | 6 | $162 |
| Sanofi-aventis U.S. LLC | 11 | $148 |
| Antares Pharma, Inc. | 8 | $121 |
| AbbVie | 7 | $109 |
| Radius Health, Inc. | 5 | $79 |
| Kyowa Kirin, Inc. | 4 | $79 |
| Dexcom, Inc. | 4 | $64 |
| Corcept Therapeutics | 3 | $57 |
| Amneal Pharmaceuticals LLC | 3 | $45 |
| IBSA Pharma Inc. | 3 | $43 |
| Bayer | 2 | $41 |
| Tandem Diabetes Care, Inc. | 2 | $38 |
| Sequel Med Tech, LLC | 2 | $37 |
| Amryt Pharma Holdings Ltd | 2 | $33 |
| Ultragenyx Pharmaceutical Inc. | 2 | $33 |
| BETA Bionics, Inc. | 2 | $32 |
| Ascendis Pharma Endocrinology Inc | 1 | $26 |
| Madrigal Pharmaceuticals | 1 | $24 |
| Averitas Pharma Inc. | 1 | $23 |
| Senseonics, Incorporated | 1 | $20 |
| Merck | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| Globus Medical | 1 | $18 |
| Lifescan, Inc. | 1 | $16 |
| Halozyme Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,975 in reported general payments places this provider in the 70th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
See all endocrinology, diabetes & metabolism providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 198 | $217,579 |
| OzempicSemaglutide | 123 | $201,692 |
| MounjaroTirzepatide | 130 | $154,718 |
| TrulicityDulaglutide | 113 | $140,062 |
| Tresiba Flextouch U-200Insulin Degludec | 36 | $66,987 |
| JanuviaSitagliptin Phosphate | 51 | $59,265 |
| TradjentaLinagliptin | 51 | $49,901 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $48,600 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $38,508 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 53 | $37,874 |
| Novolog FlexpenInsulin Aspart | 79 | $33,932 |
| Tresiba Flextouch U-100Insulin Degludec | 32 | $32,984 |
| Humalog Kwikpen U-100Insulin Lispro | 48 | $29,381 |
| FarxigaDapagliflozin Propanediol | 27 | $28,926 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 136 | $28,872 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $246 | $302,973279 claims |
| Boehringer IngelheimJardiance, Tradjenta | $162 | $267,480249 claims |
| Novo NordiskOzempic | $603 | $201,692123 claims |
| MerckJanuvia, Janumet | $19 | $84,14186 claims |
| AstraZenecaFarxiga | $1,254 | $28,92627 claims |
| AbbVieSynthroid | $109 | $10,724125 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $45 | $7,828780 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
Other endocrinology, diabetes & metabolism in Indianapolis
- Ernest AsamoahIndianapolis$959K
- Hisham AllababidiIndianapolis$195K
- Michael EconsIndianapolis$74K
- Carmella Evans-MolinaIndianapolis$55K
- Manuel Bello SeguraIndianapolis$44K
- Moazzam HabibIndianapolis$29K
- James EdmondsonIndianapolis$10K
- James ScheidlerIndianapolis$8K
- Cary MariashIndianapolis$6K
- Munro PeacockIndianapolis$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.